Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why PTC Therapeutics, Inc. Dropped Today


Why PTC Therapeutics, Inc. Dropped Today

PTC Therapeutics (NASDAQ: PTCT) fell 10.9% on Tuesday after disclosing data for RG7916 in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).

It's been a roller coaster for PTC Therapeutics, falling last week after FDA briefing documents didn't paint its Duchenne muscular dystrophy drug, Translarna, in the best light. The advisory committee agreed, voting 10-1 against recommending an approval, but investors sent shares higher, hoping the agency might ignore its panel of outside experts.

Now PTC is out with data for a different drug, RG7916, at the 22nd International World Muscle Congress. There doesn't seem to be anything inherently wrong with the data, but it wasn't super-exciting, either; this may be a sell-the-news kind of event rather than a long-term valuation change.

Continue reading


Source: Fool.com

Ionis Pharmaceuticals Inc. Stock

€47.83
2.520%
There is an upward development for Ionis Pharmaceuticals Inc. compared to yesterday, with an increase of €1.18 (2.520%).
Currently there is a rather positive sentiment for Ionis Pharmaceuticals Inc. with 26 Buy predictions and 5 Sell predictions.
As a result the target price of 56 € shows a slightly positive potential of 17.08% compared to the current price of 47.83 € for Ionis Pharmaceuticals Inc..
Like: 0
Share

Comments